IceCure Medical Ltd.

IceCure Medical Ltd.

NNASDAQ:ICCM
0.76
USD
+0.03
(+4.12%)
-6.44EPS
16.65MMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.77
6.11
1.53
0.9
0.93
0.72
1.04
6.65
4.27
2.45
2.12
1.9
1.59
1.51
Basic EPS, GAAP
-216.3
-26.94
-7.53
-4.73
-3.89
-2.38
-2.99
-6.41
-10.2
-13.5
-9.63
-8.86
-7.1
-6.44
Free Cash Flow per Basic Share
-168.32
-19.55
-6.73
-4.56
-3.56
-2.11
-1.16
-6.72
-13.55
-12.07
-8.57
-7.31
-6.89
-6.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
74.4
8.39
2.98
-0.4
2.09
1.49
8.23
22.18
16.4
7.83
3.59
3.71
3.47
Tangible Book Value per Share
- -
74.4
8.39
2.98
-0.4
2.09
1.49
8.23
22.18
16.4
7.83
3.59
3.71
3.47
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
2
2
2
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
4
4
3
3
3
3
4
Operating Margin (%)
-1,058.06
-383.27
-462.59
-496.18
-386.56
-295.76
-278.03
-107.08
-234.99
-542.59
-482.38
-476.94
-446.7
-423.69
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-5
-1
-1
-1
-1
-1
-1
-4
-10
-17
-15
-15
-15
-17
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,289.96
-441.14
-491.81
-522.82
-417.15
-329.7
-288
-96.43
-239.13
-550.34
-453.76
-465.45
-445.61
-427.67
Working Capital
- -
1
1
1
- -
1
1
6
26
24
10
5
8
11
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Total Equity
- -
- -
1
1
- -
1
1
6
27
25
12
7
9
12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-131.86
-110.8
- -
- -
-166.41
-116.39
-60.69
-64.83
-77.97
-160.7
-188.78
-228.31

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
3
Market Capitalization
45
24
17

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13
12
17
Cash, Cash Equivalents & STI
9
8
12
Accounts Receivable, Net
- -
- -
- -
Inventories
3
3
3
Total Current Liabilities
5
5
6
Payables & Accruals
2
1
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-54.44%
61.47%
31.15%
Free Cash Flow
84.36%
49.95%
15.64%
Net Income, GAAP
44.16%
45.2%
-1.7%
Sales/Revenue/Turnover
81.27%
-1.84%
2.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
3
2025
1
1
1
1
3
2026
1
1
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.27
-1.84
-2.37
-2.37
-8.86
2025
-1.87
-1.69
-1.77
-1.75
-7.1
2026
-1.74
-1.31
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Eyal Shamir
Full Time Employees
69
Sector
Health technology
Industry
Medical specialties
Address
7 Ha’Eshel Street Caesarea HA Israel 3079504
IPO Date
Feb 2, 2011
Business
IceCure Medical Ltd (Nasdaq: ICCM), a commercial-stage medical device company founded in 2006 and headquartered in Caesarea, Israel, researches, develops, and markets liquid nitrogen-based cryoablation systems, disposables, and technologies for the minimally invasive treatment of benign and malignant tumors in women's health and interventional oncology. The company offers the ProSense system, a single-probe cryoablation platform using liquid nitrogen to generate ultra-cold temperatures for creating large lethal zones in tumors such as malignant breast tumors (FDA-cleared in October 2025 for patients aged 70+ with low-risk tumors ≤1.5 cm treated with endocrine therapy), kidney, lung, liver, and bone cancers; the IceSense3 system for ablation across urology (prostate cancer, BPH), oncology, dermatology (skin cancers, warts), gynecology, general surgery (breast fibroadenomas), thoracic surgery, ENT, proctology (hemorrhoids, pilonidal cysts), and palliative care; and developmental-stage systems including XSense (single-probe) and MultiSense (multi-probe for larger tumors). IceCure operates in the United States, Europe (including recent regulatory approval for ProSense in Switzerland covering breast, lung, liver, and kidney indications), Japan (via partner Terumo Corporation, with regulatory submission planned for H1 2026), Israel, India, China, and other international markets, targeting physicians in interventional radiology, oncology, urology, and surgery for office-based and CT-guided procedures. Recent developments include FDA marketing authorization for ProSense in early-stage low-risk breast cancer in October 2025, promotion of Shay Levav to Chief Operating Officer in November 2025 to support U.S. commercial scaling to 30 sites, closure of a $10 million over-subscribed rights offering in August 2025, submission of next-generation XSense to Israeli regulators, positive interim ICESECRET kidney study results (88.7% recurrence-free rate for tumors ≤3 cm presented in March 2025), and ongoing post-market study protocols with the FDA.

Company News

  • IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026

  • IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

  • IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

  • IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

  • Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis

  • IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

  • IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

  • IceCure Medical Ltd. (NASDAQ:ICCM) Stock Now Rated “Hold” by Sell-Side Analysts

  • Reviewing IceCure Medical (NASDAQ:ICCM) & Precision Optics (NASDAQ:POCI)

  • IceCure Secures China NMPA Approval for ProSense Cryoablation System

  • IceCure Medical Receives Regulatory Approval to Market ProSense® in China

  • IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

  • West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

  • IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

  • IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript

  • IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

  • IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

  • IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

  • IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

  • IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site